Phase i study of multi-gene cell therapy in patients with peripheral artery disease

Vascular Medicine (United Kingdom)

Volumn 21, Issue 1, 2016, Pages 21-32

  Grossman, P Michael ^a   Mohler, Emile R ^b   Roessler, Blake J ^c   Wilensky, Robert L ^b   Levine, Bruce L ^d   Woo, Edward Y ^d   Upchurch, Gilbert R ^c   Schneiderman, Jacob ^e   Koren, Belly ^f,g   Hutoran, Marina ^f,g   Gershstein, Diana ^f,g   Flugelman, Moshe Y ^f,g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e SHEBA MEDICAL CENTER   (Israel)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g MultiGene Vascular Systems Ltd   (Israel)

Author keywords

cell therapy; claudication; peripheral artery disease; vascular

Indexed keywords

ANGIOPOIETIN 1; VASCULOTROPIN 165; ANGIOGENIC PROTEIN; ANGPT1 PROTEIN, HUMAN; TELOMERASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANG 1 GENE; ANKLE BRACHIAL INDEX; ARTICLE; AUTOTRANSPLANTATION; CELL THERAPY; CELL TRANSFER; CLAUDICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FOLLOW UP; GENE EXPRESSION; GENE THERAPY; HUMAN; ILIAC ARTERY OBSTRUCTION; IN VITRO STUDY; MALE; MUTLIGENE CELL THERAPY; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE FIBER; TREADMILL TEST; TREATMENT OUTCOME; VEGF165 GENE; WALKING; AGED; ANGIOGENESIS; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CELL TRANSPLANTATION; CLINICAL TRIAL; CONVALESCENCE; EXERCISE TEST; EXERCISE TOLERANCE; GENETIC TRANSDUCTION; GENETICS; INTERMITTENT CLAUDICATION; METABOLISM; MICHIGAN; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PENNSYLVANIA; PERIPHERAL ARTERIAL DISEASE; PHASE 1 CLINICAL TRIAL; PROCEDURES; SMOOTH MUSCLE CELL; TIME FACTOR; TRANSPLANTATION;

AGED; ANGIOGENIC PROTEINS; ANGIOPOIETIN-1; ANKLE BRACHIAL INDEX; CELL PROLIFERATION; CELL TRANSPLANTATION; CELLS, CULTURED; ENDOTHELIAL CELLS; EXERCISE TEST; EXERCISE TOLERANCE; GENETIC THERAPY; HUMANS; INTERMITTENT CLAUDICATION; MALE; MICHIGAN; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; PENNSYLVANIA; PERIPHERAL ARTERIAL DISEASE; RECOVERY OF FUNCTION; TELOMERASE; TIME FACTORS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84961315776     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X15612148     Document Type: Article

References (34)

1. Eraso LH, Fukaya E, Mohler ER III, et al. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. Eur J Prev Cardiol 2012; 21: 704-711.
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: E463-E654.
3. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: Six-month outcomes from the Claudication: Exercise Versus Endoluminal Revascularization (Clever) Study. Circulation 2012; 125: 130-139.
4. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (Tasc II). J Vasc Surg 2007; 45 Suppl S: S5-67.
5. Gluzman Z, Koren B, Preis M, et al. Endothelial cells are activated by angiopoeitin-1 gene transfer and produce coordinated sprouting in vitro and arteriogenesis in vivo. Biochem Biophys Res Commun 2007; 359: 263-268.
6. Simons M., Angiogenesis: Where do we stand now? Circulation 2005; 111: 1556-1566.
7. Schaper W., Collateral circulation: Past and present. Basic Res Cardiol 2009; 104: 5-21.
8. Thomas M, Augustin HG., The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-137.
9. Lucitti JL, Mackey JK, Morrison JC, et al. Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 And 17. Circ Res 2012; 111: 1539-1550.
10. Ouma GO, Jonas RA, Usman MH, et al. Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vasc Med 2012; 17: 174-192.
11. Hori M, Nakamachi T, Rakwal R, et al. Unraveling the ischemic brain transcriptome in a permanent middle cerebral artery occlusion mouse model by DNA microarray analysis. Dis Model Mech 2012; 5: 270-283.
12. Huang da W, Sherman BT, Lempicki RA., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
13. Huang da W, Sherman BT, Lempicki RA., Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
14. Preis M, Cohen T, Sarnatzki Y, et al. Effects of fibulin-5 on attachment, adhesion, and proliferation of primary human endothelial cells. Biochem Biophys Res Commun 2006; 348: 1024-1033.
15. Gardner AW, Skinner JS, Vaughan NR, et al. Comparison of three progressive exercise protocols in peripheral vascular occlusive disease. Angiology 1992; 43: 661-671.
16. Auerbach O, Garfinkel L., Atherosclerosis and aneurysm of aorta in relation to smoking habits and age. Chest 1980; 78: 805-809.
17. Aviv H, Khan MY, Skurnick J, et al. Age dependent aneuploidy and telomere length of the human vascular endothelium. Atherosclerosis 2001; 159: 281-287.
18. Hsiao R, Sharma HW, Ramakrishnan S, et al. Telomerase activity in normal human endothelial cells. Anticancer Res 1997; 17: 827-832.
19. Minamino T, Komuro I., Role of telomere in endothelial dysfunction in atherosclerosis. Curr Opin Lipidol 2002; 13: 537-543.
20. Minamino T, Miyauchi H, Yoshida T, et al. Vascular cell senescence and vascular aging. J Mol Cell Cardiol 2004; 36: 175-183.
21. Chang E, Harley CB., Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A 1995; 92: 11,190-11,194.
22. Armstrong L, Lako M, Lincoln J, et al. mTert expression correlates with telomerase activity during the differentiation of murine embryonic stem cells. Mech Dev 2000; 97: 109-116.
23. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: Revised Version. J Vasc Surg 1997; 26: 517-538.
24. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a Phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153: 874-880.
25. Kastrup J., Gene therapy and angiogenesis in patients with coronary artery disease. Expert Rev Cardiovasc Ther 2010; 8: 1127-1138.
26. Rajagopalan S, Mohler EE III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938.
27. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (The Traffic Study): A randomised trial. Lancet 2002; 359: 2053-2058.
28. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011; 124: 1765-1773.
29. Ouma GO, Zafrir B, Mohler ER III, et al. Therapeutic angiogenesis in critical limb ischemia. Angiology 2013; 64: 466-480.
30. Marandin A, Dubart A, Pflumio F, et al. Retrovirus-mediated gene transfer into human CD34+38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 1998; 9: 1497-1511.
31. Movassagh M, Desmyter C, Baillou C, et al. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 1998; 9: 225-234.
32. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
33. Royen NV, Piek JJ., Therapeutic manipulation of the collateral circulation-Future directions. Coron Artery Dis 2004; 15: 399-403.
34. Chae JK, Kim I, Lim ST, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 2000; 20: 2573-2578.